What do oncologists need to know about biosimilar products?
نویسندگان
چکیده
Many biologic products have improved the outcomes of cancer patients, but the costs can substantially burden healthcare systems. Biosimilar products can potentially reduce drug costs and increase patient access to beneficial treatments. Approval of a biosimilar product relies on the demonstration of "comparability" or "no clinically meaningful differences" as compared to its reference biologic product. Biosimilar products for erythropoietin, granulocyte colony-stimulating factor, trastuzumab, and rituximab are already available, and the regulatory processes in various countries are constantly evolving. It is important that oncologists be familiar with the potential issues surrounding the clinical use of biosimilar products. In this review article, we provide background information about biosimilar products and their regulatory approval processes, followed by a discussion of individual biosimilar drugs.
منابع مشابه
Biosimilars: what clinicians should know.
Biosimilar medicinal products (biosimilars) have become a reality in the European Union and will soon be available in the United States. Despite an established legal pathway for biosimilars in the European Union since 2005 and increasing and detailed regulatory guidance on data requirements for their development and licensing, many clinicians, particularly oncologists, are reluctant to consider...
متن کاملDiagnostic and therapeutic challenges for dermatologists: What shall we do when we don’t know what to do?
What shall we do when we have done everything we could for the diagnosis and treatment of a patient, but were not successful? What shall we do when there is no definite treatment for a patient? What shall we do when we have no diagnosis or treatment for a patient? Some useful suggestions are presented here to get rid of these situations.
متن کاملBiosimilars: Extrapolating the evidence. A roundtable discussion
Biological anticancer therapies developed in recent decades have contributed to improvements in patient care for serious illnesses. Patents for several biologics will soon expire, paving the way for initiating approval processes for biosimilarsddefined as highly similar versions of already licensed or approved biological therapies. The aim of developing a biosimilar is to establish similarity i...
متن کاملHigh Stakes Require More Than Just Talk: What to Do About Corruption in Health Systems; Comment on “We Need to Talk About Corruption in Health Systems”
Reluctance to talk about corruption is an important barrier to action. Yet the stakes of not addressing corruption in the health sector are higher than ever. Corruption includes wrongdoing by individuals, but it is also a problem of weak institutions captured by political interests, and underfunded, unreliable administrative systems and healthcare delivery models. We ur...
متن کامل